Dextrose boluses versus burette dextrose infusions in prevention of hypoglycemia among preterms admitted at Mulago Hospital: an open label randomized clinical trial. by Kutamba, E et al.
Dextrose boluses versus burette dextrose infusions in prevention of  hypoglycemia among 
preterms admitted at Mulago Hospital: an open label randomized clinical trial.
Kutamba E1, Lubega S1, 2, Mugalu J1, 2, Ouma J3, Mupere E1
1. Department of  Paediatrics and Child Health, Makerere College of  Health Sciences, Kampala, Uganda,
2. Ministry of  Health Kampala Uganda, 3 Management Sciences for Health-Kampala
Abstract
Background: Hypoglycemia is a major cause of  morbidity and mortality among preterm infants and its management 
remains a challenge in resource limited settings.  Use of  dextrose infusion by the recommended infusion pumps is not 
feasible in our environment due to their high costs and yet the current use of  mini dextrose boluses with syringes as adapted 
at Mulago national referral and tertiary teaching hospital has unknown efficacy in prevention of  hypoglycemia 
Objective: We determined the efficacy of  dextrose infusions by burettes versus two hourly dextrose boluses in prevention 
of  hypoglycemia among preterms admitted in the first 72 hours at Special Care Unit, Mulago Hospital.
Methods: One hundred and forty preterms aged 0 to 24 hours of  life were randomized to receive 10% IV dextrose either 
as mini boluses or by infusion using burettes in an open label clinical trial. Blood glucose was measured at 0, two hourly for 
next 6 hours, 6 hourly for next 12 hours and thereafter 12 hourly until end of  72 hours following admission.  Primary end 
point was incidence of  hypoglycemia (random blood sugar (RBS) < 2.6mmol/l) which was expressed as relative risk (RR). 
Efficacy of  the dextrose infusion was computed using 1-RR.
Results: From February 2012 to April 2012, 68 preterms in the bolus arm and 72 in the infusion arm were studied. 
Hypoglycemia was detected in 34% (48/140). The incidence of  hypoglycemia in the bolus arm was 59% (40/68) compared 
to 11% (8/72) in the infusion arm (RR; 0.19, 95% CI; 0.09-0.37). Efficacy (1-RR) of  infusion by burettes versus boluses in 
prevention of  hypoglycemia among preterms was 0.81 (95% CI; 0.63-0.90).
Conclusion: Continuous 10% dextrose infusion by burettes reduced the incidence of  hypoglycemia by 81% in the first 72 
hours of  admission compared to two hourly 10% mini dextrose boluses among preterms admitted at Special Care Unit, 
Mulago Hospital.(ClinicalTrials.gov Identifier: NCT01688674)
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Introduction
Prematurity and low birth weight contribute 29% of  
the total newborn deaths globally(1) and hypoglycemia 
is one of  the major complications of  prematurity. 
The overall incidence has been reported to be 1 to 5 
per 1000 live births and the risk is highest in preterm 
infants (2).  There is paucity of  data regarding incidence 
of  hypoglycemia among preterm infants in developing
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countries.  Prematurity accounts for 25% of  newborn 
deaths in Uganda(3). Challenges in prevention of  
hypoglycemia may contribute to the high mortality 
among preterm infants.  The World Health Organization 
(WHO) recommends early initiation of  breastfeeding 
(first one hour) as the most effective method of  
preventing hypoglycemia in newborns. However where 
enteral feeding is not possible, the WHO recommends 
continuous 10% dextrose by infusion pumps to prevent 
hypoglycemia among newborns(4). Most resource limited 
settings may not afford infusion pumps to administer 
continuous 10% dextrose.  Currently dextrose boluses 
of  10% given every two hours using disposable syringes 
referred to as mini dextrose boluses have been adapted 
at the national referral  and tertiary teaching Special Care 
Unit Mulago hospital, Kampala, Uganda(5). However 
efficacy of  mini dextrose at preventing hypoglycemia 
in Uganda is unknown to justify the continued use. 
Burette infusion sets which are cheaper and readily 
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available in developing countries may be an alternative 
in administering continuous 10% dextrose.
We undertook an open label randomized clinical trial to 
assess whether IV 10% dextrose given as mini boluses 
compared to burette infusion had similar efficacy in 
prevention of  hypoglycemia among preterm infants.
Methods:
Study design and setting. 
This was an open label randomized clinical trial. The 
study was conducted at Mulago Hospital’s special care 
unit, Uganda’s teaching and referral hospital. It admits 
both full term and preterm infants for specialized care 
from the capital city and referrals from other parts of  
the country.
Outcome measures 
The primary outcome measure was incidence of  
hypoglycemia to establish the efficacy of  administering 
10% dextrose using two hourly mini boluses versus 
continuous infusion by burettes in prevention of  
hypoglycemia. A preterm was considered to have 
developed hypoglycemia if  the random blood sugar 
(RBS) was < 2.6 mmol/l. The measure for efficacy 
was incidence proportion, which was determined by 
the proportion of  new cases of  hypoglycemia. This 
was expressed as a relative risk (RR) and efficacy was 
calculated as 1-RR.
The secondary outcome was observed survival of  
preterms at the end of  the 72 hour period.
This was measured as the proportion of  patients 
remaining alive from the time of  enrolment until end 
of  72 hours.
Ethical issues
Permission to conduct the study was obtained the 
Makerere School of  Medicine Research and Ethics 
Committee (SOMREC). Written consent was obtained 
from the mothers for enrollment into the study.  A data 
and safety monitoring board (DSMB) was set up to 
oversee to activities of  the research.
Sample size
We planned an interventional study of  preterm infants 
receiving dextrose by either burette infusion sets or 
boluses that are routinely used in the neonatal unit at 
Mulago hospital. Prior data indicated that the incidence 
of  hypoglycemia in the infusion arm was 27%(6), If  the 
boluses increased the incidence of  hypoglycemia by 30% 
and true relative risk of  hypoglycemia in the infusion 
arm was 0.77 relative to the bolus arm, we needed to 
study 84 patients in infusion arm and 84 patients in the 
bolus arm to be able to reject the null hypothesis that 
the relative risk equals 1 with probability (power) of  
0.9.The type I error probability associated with the test 
of  this null hypothesis was assumed to be 0.05. Thus, 
a total of  168 preterm infants were to be enrolled into 
the study. We used an uncorrected chi-squared statistic 
to evaluate the null hypothesis.  Sample size calculation 
was performed using  PS (Power and size) software(7)
This sample size was adequate to carry out a three stage 
interim analysis. The first analysis was done at 50% 
accrual; the second analysis was done at75% and the 
final analysis at the end of  the study.
Participants and recruitment
We enrolled preterms aged 0 to 24 hours of  life admitted 
to the Mulago’s special care unit from February to April 
2012 with a RBS of  ≥2.6mmol/l and birth weight 
of  ≥1kg. We excluded all preterms who had gross 
congenital abnormalities, very sick (Apgar score ≤5 at 5 
minutes) and an abandoned or orphaned preterm infant 
at the time of  recruitment. 
Trained research nurses consented patients, monitored 
random blood sugar and administered the interventions. 
The principal investigator also participated in 
recruitment, and monitoring of  study participants and 
ensuring study protocols were strictly followed. Blood 
sugar was tested using a digital glucometer (Optium 
Xceed, Abbott Laboratories Ltd). 
Randomization, blinding and treatment allocation
Eligible preterm infants were enrolled in a serial order 
and randomized to receive 10% dextrose either by 
burette infusions or two hourly mini boluses for 72 
hours during admission into the Mulago Hospital’s 
Special care unit. The randomization list was generated 
using a computer by a statistician not involved in the 
implementation of  the study. Block randomization was 
used with a block size of  four. Randomization codes 
indicating the treatment arm were sealed in opaque 
envelopes which were sequentially numbered. The study 
nurse gave the intervention according to the envelopes.
Intervention
The use of  2 hourly 10% dextrose mini boluses was the 
standard of  care in Mulago hospital and the infusion 
by burette sets was the experimental arm under study. 
Intravenous 10% dextrose was prepared by adding 50 
mls of  50% dextrose to 450 mls of  5% dextrose to 
obtain 500 mls of  10% dextrose. 
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Once an envelope was opened to see the study group 
to be assigned, the patient had an intravenous cannula 
inserted and a study nurse administered 10% dextrose 
according to protocol. 
Daily Fluid requirements of  10% dextrose were 
calculated for the 72 hours of  follow as 80 mls/kg/day, 
100 mls/kg/day and 120 mls/kg/day for day 1, 2 and 3 
respectively as per SCU protocol (see appendix 5). The 
infusion rate was calculated as drops per minute and 
cross-checked every thirty minutes to ensure regular 
flow. The burette administers 60drops/ml (Poly Vol 
Burette set manufactured by Poly Medicure Ltd). The 
infusion rate was calculated every 24 hours for the 3 
days of  follow up as; [[Total fluid volume (mls) x Birth 
weight (kg)] /1440 minutes] x60= drops/min]. For 
the preterms in the bolus arm, the total volume was 
given as two hourly boluses each pushed over 1 minute 
(total volume required per kg body weight per 24 hours 
divided by 12; to obtain the volume of  10%D to be 
given every two hours). 
Blood glucose monitoring
Blood sugar tests were done at time of  recruitment, 
every 2 hourly for the first 6 hours then 6 hourly until 
end of  the first 12 hours and then 12 hourly until 72 
hours of  admission.  For preterms in the bolus arm 
blood sugar testing was done before administration of  
dextrose boluses. At the end of  the study period the 
preterms were handed over to the clinical team in SCU 
to continue with routine care. After the initial episode of  
hypoglycemia, the hypoglycemia was treated by giving 
them IV 10% dextrose boluses and the preterms were 
still followed until the end of  72 hours of  admission 
to determine survival. Preterms who were found to 
have hyperglycemia (blood sugar>10mmol/l) had their 
blood glucose tested every 30minutes until the blood 
glucose was below 10 mmol/l.
Follow up
Preterm infants were followed up until discharge, death 
or a maximum of  72 hours
Data management and analysis: 
Data was entered on Case Report Forms (CRFs), 
cleaned and entered into the computer using Microsoft 
Access 2007. The Data was then exported to STATA 
version 10 for analysis. Analysis was by intention-to-treat 
method. Data were summarized in form of  proportions, 
percentages or frequencies and presented in frequency 
tables. Incidence proportion of  hypoglycemia with 
the associated 95% CIs was determined for the two 
study arms. Incidence proportion and relative risk were 
determined using chi-square tests. The efficacy of  10% 
dextrose infusion by burettes compared to two hourly 
10% dextrose boluses was calculated using the following 
expression: 1- RR. (RR = Relative Risk)
  Sub-analysis was done for overall hypoglycemic 
distributions for infants receiving boluses or infusions. 
These were estimated using the Kaplan-Meier method 
and compared using the log-rank test. The time to 
development of  hypoglycemia and the intervention 
status were used as the primary dependent and 
independent variables, respectively in the model. The 
secondary objective was the proportion of  preterms 
surviving by the end of  72 hour period of  follow up. 
Interim analysis done at 75% recruitment was reviewed 
by the DSMB and recommended to stop the trial because 
of  overwhelming benefit by the dextrose infusions as 
compared to the two hourly dextrose boluses.
Results: 
Between February and April 2012, 260 preterms aged 
less than 24 hours of  life were screened for eligibility 
and of  these, 115 (44%) had hypoglycemia at admission 
and 5 were excluded because they were very sick. Of  
the 140 (54%) preterms who were enrolled into the 
study 68 were randomized into the mini bolus arm, and 
72 into the infusion arm and analyzed respectively. The 
mean gestational age (weeks) was 31.4 (SD=2.7) in bolus 
arm and 31.2 (SD=2.2), (p=0.655) in infusion arm, and 
mean RBS at enrolment (mmol/l) was 3.9 (SD=1.3) in 
bolus arm and 4.1 (SD=1.5), (p=0.723) in infusion arm. 
The mean age (hrs) was 2.3(SD=2.5) and 2.6 (SD=2.8), 
(p=0.512) in bolus arm and infusion arm respectively. 
The mean birth weight (Kg) was 1.8 (SD=0.4) in bolus 
arm and 1.7 (SD=0.3), (p=0.137) in infusion arm. Mean 
temperature (0C) was 34.4 (SD=4.3), (p=0.989) in bolus 
arm and 34.4 (SD=4.4) in infusion arm and the mean 
Apgar score was 8.0(SD=1.2) in bolus arm and 8.2 
(SD=1.2), (p= 0.534) in infusion arm. There were more 
males (52.9%) than females (47.1%). Except for more 
preterms in the bolus arm who initiated enteral feeding 
< 48hrs than those in the infusion arm there was no 
statistical difference in the baseline characteristics 
(Table 1A&B).
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Table 1 A: Neonatal baseline characteristics among preterms receiving 10% dextrose in the 1st 72hrs of  




n=72    (%)
P-value
Sex of  the baby
Male 36 (48.7) 38 (51.4)
Female 32 (48.5) 34 (51.5) 0.985
Birth type
Singleton 49 (48.5) 52 (51.5)
Twin + 19 (52.8) 17 (47.3) 0.660
Size at birth
SGA 5(41.8) 7.0 (58.3)
LGA 16(51.6) 15 (48.4)
AGA 47(48.5) 50 (51.6) 0.842
Sucking reflex 
Poor 21(44.7) 26 (55.3)
Good 47(50.5) 46 (49.5) 0.513
Mode of  delivery 
SVD 48(50.5)            47 (49.5)
C/S 15(39.5) 23 (60.5) 0.249
Start of  Enteral feeding
≤48hrs 50 (83.3) 45 (67.2)
>48hrs 10 (16.7) 22 (32.8) 0.036
Table 1B: Maternal baseline characteristics among preterms receiving 10% dextrose in the 1st 72hrs of  
admission at SCU-Mulago Hospital, 2012.
Variable Bolus (%)        Infusion (%) P-value
Marital status
Married                                                                    53 (50.0)                      53 (50.0)
Not married     13 (43.3)                      17 (56.7)             0.519
Attended ANC
Yes      63 (49.2)                       65 (50.8)  
No        4 (40.0)                         6 (60.0)              0.574
HIV status
Positive      9 (47.4)                         10 (52.6)  
Negative      50 (48.1)                         54 (51.9)  
Unknown      8 (50.0)                          8 (50.0)            0.987
Mother Hypertensive &
Drug use
Yes      5 (41.8)                         7 (58.3)
No      62 (49.2)                        64 (50.8)            0.618
Intrapartum Dextrose use
Yes      24 (52.2)                        22 (47.8)
No                                 44 (47.3)                         50 (53.2)            0.551
Parity 
Primegravida      26 (50.9)                            25 (49.0)
Multigravida     42 (47.2)                       47 (52.8)                         0.660
Residence
Rural      12 (46.1)                       14 (53.9)
Urban      53 (47.8)                        58 (52.3)          0.884
The total time of  follow up to development of  
hypoglycemia among study participants was 8112 
person hours (3320 and 4792 person hours among the 
bolus and infusion arms respectively).    Forty eight (48) 
out of  one hundred and forty (140) patients developed 
hypoglycemia with the overall incidence of  34%.  Forty 
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out of  sixty eight (59%) preterms in the bolus arm, 
compared to eight out of  seventy two (11%) in the 
infusion arm developed hypoglycemia. 
Time to development of  hypoglycemia was shorter 
among the preterms receiving 10% dextrose mini 
boluses as compared to those in the infusion arm 
(Figure 2). 
Figure 2. Time to development of  hypoglycemia among preterms receiving 10% dextrose by either two hourly 
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68 56(11) 41(13) 35(6) 0(10)Bolus
Number at risk
0 20 40 60 80
Time (hours)
expvar = Bolus expvar = Infusion
Survival function among pre-terms
P<0.001
When compared with the 10% dextrose boluses, 10% 
dextrose infusion by burettes reduced the incidence 
of  hypoglycemia by 81% among preterms admitted in 
SCU in the first 72 hours (Table 2).
Table 2:  Incidence proportion of  hypoglycemia among preterms admitted in the 1st 72hrs of  admission 
at SCU-Mulago Hospital, 2012
Infusion (n=72) Bolus (n=68) (95% CI)
Hypoglycemia         8 40
Incidence proportion         0.11 0.59
Relative Risk (RR) 0.19 0.09- 0.37
Efficacy (1-RR) 0.81 0.63- 0.90
The overall survival among preterms was high at 
97% (136/140). 70/72 (97.2%) in the infusion arm 
compared to 66/68 (97.1%) preterms in the bolus arm 
that survived. Only four deaths (4/140) occurred during 
the study period and none had hypoglycemia. Among 
the preterms who died, three out of  four (75%) had 
hyperglycemia (RBS >10 mmol/l). The mean age (±SD) 
among preterms who died was 1.8 (1.5) hours compared 
to 2.5 (2.7) hours among those who survived
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Figure 1. Trial profile
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This study was carried out to establish the efficacy 
of  using 10% dextrose mini boluses versus dextrose 
infusions by burettes in prevention of  hypoglycemia 
among preterms admitted in the first 72 hours at Mulago 
hospital. The measure of  efficacy was the incidence 
proportion of  hypoglycemia in the two study groups, 
expressed as a relative risk. In this randomized clinical 
trial, we found that using 10% dextrose infusion by 
burettes reduced the incidence of  hypoglycemia among 
preterms by 81% compared to dextrose boluses. 
This implies that 10% dextrose infusion by burettes is 
preferred to 10% dextrose mini boluses in prevention 
of  hypoglycemia of  hypoglycemia among preterms. 
This study is probably the first randomized clinical trial 
to be conducted in Africa to determine the efficacy of  
using 10% dextrose infusion by burettes compared to 
dextrose boluses in prevention of  hypoglycemia among 
preterms. 
The only available study was conducted by Lilien et 
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al in USA, who found that 18 out of  22 neonates’ 
glucose levels rose above the hypoglycemic range 
within ten minutes of  initiating 10% dextrose infusion. 
He also showed that, constant glucose infusion was 
therapeutically useful for treatment of  neonatal 
hypoglycemia(8). There are no documented comparative 
studies that have analyzed the efficacy of  10% dextrose 
boluses and 10% dextrose infusion by burettes in 
prevention of  hypoglycemia among preterms. In this 
study the overall incidence of  hypoglycemia among 
preterms was high (34%). Similar to this study,  Alaroker 
et al in Mulago hospital showed a high prevalence (36%) 
of  hypoglycemia among preterms(9).
 The higher incidence of  hypoglycemia among 
preterms in the bolus arm (59%) could be due to the 
fact that, when dextrose boluses are administered, the 
rate of  entry into blood exceeds the capacity of  body 
cells to utilize glucose. The excess glucose stimulates 
the pancreatic β cells to secrete insulin and with 
each succeeding bolus, it decreases the threshold for 
insulin release but also inhibit glucagon release, thus 
resulting into hyperinsulinism which causes rebound 
hypoglycemia(10). It has been recommended by Lilien 
et al that when dextrose boluses are given to treat 
hypoglycemia, they should be immediately followed by a 
continuous dextrose infusion to prevent hyperglycemia 
with resultant rebound hypoglycemia(11).
 The overall survival was high (97%) in this study and it 
was similar for both study groups.
 On the other hand, Namukwaya et al in a prospective 
study at Mulago Hospital,  showed that hypoglycemia 
was associated with less survival among very low birth 
weight infants in SCU (31.6% versus 68.3% in the non-
hypoglycemic group), although the association was not 
statistically significant (P=0.498)(12). The high survival in 
this study could be explained by the fact that, this being 
an interventional study, preterms were actively followed 
up and treated as soon as hypoglycemia was detected.   
It was interesting to note that mortality was high 
(75%) among preterms who developed hyperglycemia 
in this study. This is higher than reported by Vander 
Lugt Margreth et al   in Netherlands who found 
mortality among the very low birth weight infants with 
hyperglycemia to be 41%(13). This study was however not 
powered to explore factors (including hyperglycemia) 
associated with mortality. 
Adverse events
Hyperglycemia was regarded as an adverse event in this 
study. There were almost equal numbers (29% in the 
bolus arm versus 30% in the infusion arm) of  preterms 
who developed hyperglycemia in both study groups. 
Most of  the preterms who developed hyperglycemia in 
the infusion arm were found to have a faster infusion 
rate (drops/min) than previously set.
This is comparable to Louik Carol et al in Boston 
who described hyperglycemia to occur among infants 
receiving 10% dextrose infusion and its risk increased 
with increasing dextrose dose as well as decreasing 
birth weight and gestational age(14). This study was not 
powered to explore hyperglycemia and risk factors 
among preterms.
Study limitations
This was an open label randomized clinical trial. The 
measurement of  outcome was not blinded to the study 
nurses and the investigator. However, blood glucose 
testing was done using a digital glucometer (Optium 
Xceed, Abbott Laboratories Ltd). It was difficult to 
interfere with measurement of  outcome because the 
digital glucometer had a memory function that could 
store the blood glucose value including the time and 
date of  measurement.  
Insulin and glucagon blood levels were not measured 
in this study. These hormones greatly influence glucose 
metabolism. However, the effect on the results was 
equally distributed because of  randomization.
Although the laboratory determination (hexokinase) of  
blood glucose is the gold standard for measuring glucose 
concentration, the glucometer (glucose oxidase) method 
equally has a high sensitivity (98%) and specificity (93%) 
with positive and negative predictive values of  88% and 
99% respectively(15). However, the glucometer method 
may be affected by factors like hemolysis which may 
be caused by squeezing of  the heel to obtain capillary 
blood. 
To minimize this error, squeezing of  the heel was 
avoided and warming of  the heel by gentle massage was 
ensured during collection of  capillary blood. However 
this inherent limitation was distributed in both study 
groups and therefore had limited influence on the 
results of  this study.
Conclusions: 
Continuous 10% dextrose infusion by burettes reduced 
the incidence of  hypoglycemia by 81% compared to two 
hourly 10% dextrose boluses among preterms admitted 
in the first 72 hours in SCU- Mulago Hospital. Survival 
was high among preterms admitted in the first 72 hours 
in SCU-Mulago Hospital.
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Recommendations:
We recommended that Continuous 10% dextrose 
infusion by burettes should be considered as an option in 
prevention of  hypoglycemia among preterms admitted 
in SCU at Mulago Hospital. A study is also recommended 
to determine the incidence of  hyperglycemia and risk 
factors for mortality among preterms receiving 10% 
dextrose.
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